William (Dongfang) Shi, Ph.D.
       Founder, CEO & Chairman



· 
Ph.D. in Medicinal chemistry from the University of Nottingham in 1995, and Postdoctoral at UT Austin
·  Former Senior Director at Genelabs Technologies Inc and Metabolex Inc.
·  CEO, Chairman, and co-founder of Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd
·  27 years for discovering and developing a new drug to treat gout, cancer, diabetes, and HCV



         Marc Gurwith
,M.D. & J.D.
         CMO



·  B.S. from Yale University
·  M.D. from Harvard University School of Medicine
·  Internal Medicine/Infectious Diseases from Stanford University School of Medicine
·  Former CMO and Senior Vice President at Genelabs, PaxVax, VaxGen, Wyeth Ayerst, and etc.
·  34 years for global clinical research from Phase I to Phase III


      
       Hong Farling
,Ph.D.
       Senior Director of Clinical Operation



·  Ph.D. in Biochemistry from State University of New York, and Post-doctoral at Albert Einstein College of Medicine
·  Former Director and Senior Director of Clinical Operations at Vaxart, Portola, KangLaiTe, IMDZ and etc.
·  28 years in US Pharmaceutical companies and 19 years for clinical research and operations




       Roy J. Wu, MBA
      
Senior Vice President of Global Business Development


·  B.S. in Biology from the University of San Francisco
·  MBA in International Finance from the University of San Francisco School of Business
·  Former Director of Business Development at Quintiles-BRI Inc.
·  Former Vice President and Senior Vice President of Business Development at Novabay Pharmaceuticals Inc., Genelabs Technologies Inc., and Kissei Pharma Inc.
·  
35 years in the pharmaceutical industry with increasingly responsible management positions in Business Development, Licensing, Distributor Management, International Marketing, Project Management, Clinical Development, Pacific Sector Regulatory, and Pharmaceutical Development
·  Over $160 million raised with 33 projects through equity financing activities, research collaboration and license agreements



     
Adam (Wenqing) Jin, M.S.
     Vice President of Business Development



·  M.S. in Pharmaceutical Manufacturing & Regulatory Affairs from Stevens Institute of Technology
·  Former Project Manager at Sterile Technology LLC, responsible for Process development, GMP validation and Operation
 consulting
·  Responsible for project collaboration, equity financing activities, and license agreements at Atom Bioscience
·  Completed 2 rounds of financing (Round A and A+)
·  Member of the board of directors since 2015 



     
  Danielle Armas, M.D.
       Senior Principal Investigator



·  M.D. from Myo Clinic College of Medicine 
·  Clinical Assistant Professor at University of Arizona, College of Medicine
·  8 years in Principal Investigator, Principal Investigator II and Senior Principal Investigator at Celerion



     
Andrea Stukel
      Clinical Operations Manager



·  B.S. in Biochemistry from Arizona State University 
·  12 years in positions at MDS Pharma Services and Celerion, Associate Director of Clinical Operations, Senior Clinical Study Manager, and Director of Global Project Management


 
        Mike Li
, M.S.                                                                           
        Senior Director of CMC & Regulatory


·  M.S. in Chemistry & Chemical Engineering
·  Former Sr Director of  US Pharmas
·  35 years experience in CMC development 
·  Preparation of CMC for US IND submission Tech transfer & GMP compliance


5d2e87a992660.png


         
Steven Smith
         Senior Director of Clinical DMPK



·   
Former Head of DMPK at Roche, CA
·   Senior Director and Director of DMPK at UCB Pharma, Adolor and Syntex Research
·  Over 30 years of experience in Clinical DMPK
·  Contributed to over 50 lead optimization projects.  More than 30 of these have proceeded to clinical testing and also contributed to 4 NDA approvals, with successful drugs in clinical use.